Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Publication
, Journal Article
Everson, RG; Graner, MW; Gromeier, M; Vredenburgh, JJ; Desjardins, A; Reardon, DA; Friedman, HS; Friedman, AH; Bigner, DD; Sampson, JH
Published in: Expert Rev Anticancer Ther
May 2008
Angiogenesis, the growth of new blood vessels from previously existing vasculature, is a requirement for tumor growth and metastasis. The first US FDA-approved drugs targeting angiogenesis have shown potential in the treatment of malignant gliomas. Immunotherapy as a treatment modality lends itself well to specifically targeting angiogenesis in tumors and may represent a powerful tool in the treatment of malignant gliomas. This review focuses on developments in immunotherapy targeting angiogenesis and tumor-vascular-specific endothelial cells using a variety of immunotherapeutic strategies including monoclonal antibodies and conjugated immunotoxins, as well as cellular, peptide, DNA and dendritic cell vaccines.
Duke Scholars
Published In
Expert Rev Anticancer Ther
DOI
EISSN
1744-8328
Publication Date
May 2008
Volume
8
Issue
5
Start / End Page
717 / 732
Location
England
Related Subject Headings
- Vascular Endothelial Growth Factors
- Vaccines, Subunit
- Vaccines, DNA
- Receptors, Vascular Endothelial Growth Factor
- Radioimmunotherapy
- Oncology & Carcinogenesis
- Immunotoxins
- Immunization, Passive
- Humans
- Glioma
Citation
APA
Chicago
ICMJE
MLA
NLM
Everson, R. G., Graner, M. W., Gromeier, M., Vredenburgh, J. J., Desjardins, A., Reardon, D. A., … Sampson, J. H. (2008). Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther, 8(5), 717–732. https://doi.org/10.1586/14737140.8.5.717
Everson, Richard G., Michael W. Graner, Matthias Gromeier, James J. Vredenburgh, Annick Desjardins, David A. Reardon, Henry S. Friedman, Allan H. Friedman, Darell D. Bigner, and John H. Sampson. “Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.” Expert Rev Anticancer Ther 8, no. 5 (May 2008): 717–32. https://doi.org/10.1586/14737140.8.5.717.
Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, et al. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther. 2008 May;8(5):717–32.
Everson, Richard G., et al. “Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.” Expert Rev Anticancer Ther, vol. 8, no. 5, May 2008, pp. 717–32. Pubmed, doi:10.1586/14737140.8.5.717.
Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther. 2008 May;8(5):717–732.
Published In
Expert Rev Anticancer Ther
DOI
EISSN
1744-8328
Publication Date
May 2008
Volume
8
Issue
5
Start / End Page
717 / 732
Location
England
Related Subject Headings
- Vascular Endothelial Growth Factors
- Vaccines, Subunit
- Vaccines, DNA
- Receptors, Vascular Endothelial Growth Factor
- Radioimmunotherapy
- Oncology & Carcinogenesis
- Immunotoxins
- Immunization, Passive
- Humans
- Glioma